UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 913, 2021

BIONOVATE TECHNOLOGIES CORP.

(Exact name of registrant as specified in its charter)

Nevada		333-188152		33-1229553
(State or other jurisdictionof incorporation)		(~~Commission~~CommissionFile ~~File~~ Number)		(IRS ~~Employer~~EmployerIdentification ~~Identification~~ No.)

950 W Bannock St, Boise, Idaho		83702
Gewerbestrasse 1, Cham, Switzerland		6330
(Address of principal executive offices)		(Zip Code)

Registrant ’s telephone number, including area code~~: (~~ 280) -231-1606

~~Gewerbestrasse 10, Cham, Switzerland 6330~~______________________________________________

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( §240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	None	None

Item 58.0201 ~~Departure~~Other ~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Events.

On July 913, 2021, Aleksander Vucak ~~resigned~~("Vucak") was reappointed as a director and as an officer offor our company. MrThe company decided that Timothy Jones ("Jones") appointment was not necessary. ~~Vucak’s~~This ~~resignation~~decision was not ~~the~~a result of a disagreement between ~~Mr.~~Jones ~~Vucak~~ and ~~our~~the company; onnor any matter relating to ~~our~~the company’'s operations, policies, or practices. OnItem ~~July~~12. 9,Results ~~2021,~~of ~~Timothy~~Operations ~~Jones was appointed as a director to replace Mr. Vucak~~ and ~~he was also appointed President, Chief Executive Officer, Chief~~ Financial ~~Officer, Secretary and Treasurer of our company~~Condition.

~~Mr.~~There ~~Jones,~~are ~~age~~no ~~64,~~family ~~began~~relationship ~~his~~between ~~career~~Vucak atand ~~Bayer~~any indirector ~~1983~~or asexecutive aofficer ~~sales~~of ~~manager~~our ~~after~~company ~~graduating~~and inno ~~business~~related atparty atransactions ~~university~~required into ~~the~~be ~~United~~reported ~~Kingdom.~~under ~~Mr.~~the ~~Jones~~Item ~~recently~~404(a) ~~retired~~of ~~from~~Regulations ~~his position at Bayer and is now pursuing different opportunities.~~S-K

~~There are no family relationship between Mr. Jones and any director or executive officer of our company and no related party transactions required to be reported under Item 404(a) of Regulation S-K.~~2

2SIGNATURES

~~SIGNATURES~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~Pursuant~~/s/ toAleksander ~~the~~Vucak ~~requirements~~Aleksander ofVucak ~~the~~Date: ~~Securities~~January ~~Exchange Act of 1934~~31, ~~the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~2022

~~BIONOVATE TECHNOLOGIES CORP. /s/ Timothy Jones Timothy Jones President Date: July 14, 2021~~3

Filing Compare · Bionovate Technologies Corp.